Related Experiment Video
Updated: Jul 7, 2026
05:32
Transient Middle Cerebral Artery Occlusion Model of Stroke
Published on: August 11, 2023
Opioids modulate post-ischemic progression in a rat model of stroke
Tsung-Kuei Kao1, Yen-Chuan Ou, Su-Lan Liao
1Department of Nursing, Tajen Institute of Technology, Pingtung 907, Taiwan.
Neurochemistry International
|February 26, 2008
Summary
Opioid agonists, delta and kappa, protect against brain injury after stroke by reducing inflammation. These findings suggest potential therapeutic uses for opioid compounds in neuroinflammatory diseases.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular disease research
Background:
- The opioidergic system's role in cerebral ischemia is implicated but not fully understood.
- Neuroprotection studies highlight the involvement of opioid signaling in ischemia/reperfusion (I/R) injury.
- Mechanisms underlying opioidergic neuroprotection in cerebral ischemia require further elucidation.
Purpose of the Study:
- To investigate the neuroprotective effects of intracerebroventricular administration of opioidergic agonists against cerebral ischemia in rats.
- To determine the specific mechanisms underlying any observed neuroprotective effects.
- To explore the potential of opioidergic agents in treating neuroinflammatory conditions.
Main Methods:
- Utilized a focal cerebral ischemia/reperfusion (I/R) rat model.
- Administered delta (BW373U86), kappa (Dynorphin A 1-13), and mu (TAPP) opioid agonists.
- Assessed neuroprotection via cerebral infarction size and neuronal preservation.
- Conducted antagonism assays using kappa (nor-Binaltorphimine) and delta (Naltrindole) antagonists.
- Evaluated brain edema, inflammatory cell infiltration, and IL-6 expression.
- Performed in vitro studies on stimulated glial cells.
Main Results:
- Delta (BW373U86) and kappa (Dynorphin A 1-13) agonists, but not mu agonists, attenuated cerebral ischemic injury.
- Dynorphin A's neuroprotection was kappa-dependent, while BW373U86's was opioid-independent.
- Neuroprotection correlated with reduced brain edema, inflammation, and IL-6 expression.
- Delta and kappa agonists inhibited IL-6 production in glial cells.
Conclusions:
- Opioidergic agents BW373U86 and Dynorphin A offer neuroprotection against cerebral ischemia via distinct opioid-dependent and -independent pathways.
- The neuroprotective effects are associated with immune suppression, particularly reduced IL-6.
- Opioidergic compounds show therapeutic potential for neuroinflammatory diseases, warranting further mechanistic investigation.
